HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
SB 211475
a carvedilol metabolite; structure given in first source
Also Known As:
(4-(2-hydroxy-3-((2-(2-methoxy-phenoxy)ethyl)amino)propoxyl)-9H-carbazol-3-ol); SB-211475
Networked:
2
relevant articles (
1
outcomes,
1
trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Heterocyclic Compounds: 198
Fused-Ring Heterocyclic Compounds
2-Ring Heterocyclic Compounds
Indoles: 200
Carbazoles: 32
SB 211475: 2
3-Ring Heterocyclic Compounds
Carbazoles: 32
SB 211475: 2
Organic Chemicals: 133
Amines: 4871
Amino Alcohols: 20
Propanolamines: 4
SB 211475: 2
Alcohols: 595
Amino Alcohols: 20
Propanolamines: 4
SB 211475: 2
Propanols: 3
Propanolamines: 4
SB 211475: 2
Related Diseases
1.
Shock
01/01/1998 - "
At doses of 0.5 mg kg(-1) and 1.0 mg kg(-1), SB 211475 exerted significant anti-shock and endothelial protective effects, characterized by prolonged survival times, increased survival rates, attenuated increases in tissue myeloperoxidase activity and haematocrits, and preserved endothelium-dependent vasorelaxation.
"
01/01/1998 - "
The present experiment was designed to evaluate the effects of SB 211475, a hydroxylated metabolite of the new beta-adrenoceptor antagonist, carvedilol, on rat splanchnic ischaemia (SI, 60 min) and reperfusion(R)-induced shock and tissue injury.
"
2.
Myocardial Reperfusion Injury
09/04/1998 - "
The aim of this study was to investigate the effect of SB 211475, a metabolite of carvedilol with weak alpha1-adrenoceptor antagonism and antioxidant effect, on myocardial reperfusion injury and infarct size in anesthetized rabbits.
"
3.
Infarction (Infarctions)
09/04/1998 - "
The lowest dose of SB 211475 (0.3 mg/kg) did not reduce infarct size compared to vehicle, whereas SB 211475 1.0 or 3.0 mg/kg reduced infarct size significantly compared to vehicle (41.2 +/- 2.2% and 40.5 +/- 2.8% vs. 59.1 +/- 3.9%, p < 0.05).
"
09/04/1998 - "
In conclusion, SB 211475 in the two highest doses reduced infarct size by protecting from reperfusion injury, possibly by reduced neutrophil accumulation.
"
09/04/1998 - "
Carvedilol reduced infarct size significantly more than SB 211475 1.0 and 3.0 mg/kg (28.8 +/- 3.9% vs. 41.2 +/- 2.2% and 40.5 +/- 2.7%, p < 0.05).
"
09/04/1998 - "
SB 211475, a metabolite of carvedilol, reduces infarct size after myocardial ischemic and reperfusion injury in rabbits.
"
09/04/1998 - "
The aim of this study was to investigate the effect of SB 211475, a metabolite of carvedilol with weak alpha1-adrenoceptor antagonism and antioxidant effect, on myocardial reperfusion injury and infarct size in anesthetized rabbits.
"
4.
Reperfusion Injury
09/04/1998 - "
In conclusion, SB 211475 in the two highest doses reduced infarct size by protecting from reperfusion injury, possibly by reduced neutrophil accumulation.
"
09/04/1998 - "
SB 211475, a metabolite of carvedilol, reduces infarct size after myocardial ischemic and reperfusion injury in rabbits.
"
5.
Inflammation (Inflammations)
09/04/1998 - "
Carvedilol and SB 211475 1.0 and 3.0 mg/kg reduced myeloperoxidase activity to the same extent, indicative of reduced inflammation.
"
Related Drugs and Biologics
1.
Peroxidase (Myeloperoxidase)
2.
Carvedilol (Coreg)
3.
Antioxidants
4.
Adrenergic beta-Antagonists (beta-Adrenergic Blocking Agents)